Results 281 to 290 of about 928,606 (352)

Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers. [PDF]

J Ovarian Res
Feng X, Zhang Y, Bajinka O, Ouedraogo SY, Zhang Y, Li N, Zhan X.   +6 more
europepmc   +1 more source

Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review. [PDF]

Ann Surg Oncol
Liguori L, Ventin M, Cattaneo G, Zhang L, Osipov A, Sabbatino F, Ferrone CR.   +6 more
europepmc   +1 more source

Real-world effectiveness and prognostic factors of platinum rechallenge in advanced urothelial cancer. [PDF]

BMC Cancer
Kim EJ, Kim JH, Chu J, Lee YG, Im HS.
europepmc   +1 more source

Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach.

JMIR Cancer
Marzano L, Dan A, Darwich AS, De Petris L, Tendler S, Lewensohn R, Raghothama J, Meijer S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Lancet, The, 2019
BACKGROUND Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed
Luis Paz-Ares, Katsuyuki Hotta, Mustafa ÖzgÜroglu   +2 more
exaly   +2 more sources

Cellular processing of platinum anticancer drugs

Nature Reviews Drug Discovery, 2005
Dong Wang, Stephen J Lippard
exaly   +2 more sources